ERBB3 and familial pancreatic carcinoma: In contrast, pertuzumab had almost no effect on growth of tumors derived from HER3-negative pancreatic cancer cells, demonstrating that pertuzumab is efficient in vivo only in HER3-positive pancreatic tumor xenografts.